The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.
News items for the week of Nov. 4.
UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.
The test is the second infectious disease assay from Bioneer to be CE marked, and the South Korean company has a third test in the pipeline.
The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.
Lexent's NGS assay for monitoring response to treatment and minimal residual disease for solid tumors will eventually run on the Illumina NextSeq 550Dx.
Clinicians found interpreting negative results and variants of uncertain significance to be challenging, according to an analysis presented at the NSGC annual meeting.
The project represents the UK portion of a broader initiative to sequence the genomes of all 1.5 million known animals, plants, protozoa, and fungi.
The liquid biopsy firm reported revenues of $60.8 million for the quarter, easily surpassing the consensus Wall Street estimate of $45.4 million.
The company's software-related revenues grew year over year, but its sequencing and molecular analysis revenues declined.
The San Diego-based genomic analysis firm reported $3.3 million in revenue, driven by growth in North America sales, offset by a decline in international sales.
Strong growth in instrument revenue, driven by sales of the Sequel II system, was tempered by decreased consumable revenue as customers transitioned to the new platform.
In its first quarter as a public company, the single-cell analysis firm reported $61.2 million in total revenues, beating Wall Street expectations.
Using ancient DNA, researchers retraced ancestral diversity and human migrations through Rome and central Italy going back more than 10,000 years.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.
Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.
The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.
The German company offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs.
The firm generated $56.5 million in revenue compared to $37.4 million in Q3 2018, and beat the consensus Wall Street estimate of $55.0 million
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The General Data Protection Regulation has slowed some data sharing with non-European researchers as they find ways to comply with the law, ScienceInsider reports.
A bioethicist from Abertay University uses a utilitarian approach to justify genetically modifying the human germline, the BBC reports.
The US has upgraded its network of public health labs to provide whole-genome sequencing to track antibiotic-resistant bacteria, Quartz reports.
In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings, and more.